Can-Fite BioPharma Ltd. (CANF)

Can-Fite BioPharma Ltd. (CANF) Healthcare & Pipeline Overview

Can-Fite BioPharma Ltd. is an Israeli clinical-stage biotechnology firm advancing small molecule therapeutics for cancer, inflammatory diseases, and erectile dysfunction. The company leverages its A3AR platform, with lead candidates Piclidenoson and Namodenoson in advanced clinical trials, aiming to address significant unmet medical needs through its proprietary drug development and strategic partnerships.

What Is the Investment Thesis for CANF?

Can-Fite BioPharma Ltd. presents an investment thesis centered on its advanced clinical pipeline targeting significant unmet medical needs. The company's lead candidates, Piclidenoson and Namodenoson, are in Phase III clinical trials for psoriasis and hepatocellular carcinoma (HCC), respectively, representing potential high-value markets upon successful regulatory approval. Namodenoson is also progressing in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a condition with substantial global prevalence and limited treatment options, offering a considerable growth catalyst. The proprietary A3AR platform, coupled with a developed predictive biomarker blood test, suggests a targeted approach to drug development, potentially enhancing efficacy and patient selection. Strategic collaborations, such as the agreement with CMS Medical for commercialization rights, provide a pathway for market entry and de-risk aspects of commercial development. While the company's current financial profile reflects its clinical-stage nature, with a Profit Margin of -1794.6% and a Market Cap of $2.11M, these metrics are typical for biopharmaceutical companies heavily investing in R&D prior to commercialization. The successful completion of ongoing Phase III trials and subsequent regulatory submissions are critical value drivers. The company's lean structure, with 5 employees, indicates a focus on outsourcing and partnerships, which can be efficient but also reliant on external execution. The low Beta of 0.03 suggests that company-specific news, particularly clinical trial results, will be the primary driver of stock performance.

Based on FMP financials and quantitative analysis

CANF Key Highlights

• Market Capitalization: $0.00B, reflecting its clinical-stage status and pre-revenue operations.
• Profit Margin: -1794.6%, indicative of significant research and development investments typical for a biopharmaceutical company without commercialized products.
• Gross Margin: 100.0%, as there are no cost of goods sold for commercial products at this stage of development.
• Beta: 0.03, suggesting a very low correlation with broader market movements, indicating that company-specific clinical trial news is likely a primary driver of stock performance.
• Employees: 5, highlighting a lean operational structure focused on R&D management and strategic external partnerships.

Who Are CANF's Competitors?

CANF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CANF's Key Strengths?

• Advanced clinical pipeline with lead candidates Piclidenoson and Namodenoson in Phase III trials for significant indications.
• Proprietary A3 Adenosine Receptor (A3AR) platform and a developed predictive biomarker blood test kit.
• Strategic licensing and collaboration agreements (e.g., CMS Medical, Univo Pharmaceuticals) providing development and commercialization pathways.
• Lean operational structure with 5 employees, potentially indicating efficient resource allocation for R&D.
• Targeting diseases with high unmet medical needs and large market potential (e.g., HCC, NASH, psoriasis).

What Are CANF's Weaknesses?

• Significant negative profit margin (-1794.6%) due to heavy R&D investment, typical for a clinical-stage biopharma.
• Pre-revenue stage with a Market Cap of $2.11M, indicating reliance on external funding for operations.
• High dependence on successful outcomes of ongoing and future clinical trials for drug approval and commercialization.
• Small employee base of 5, which may limit in-house capabilities and increase reliance on external partners.
• Lack of product diversification beyond its core A3AR-targeting small molecules.

What Could Drive CANF Stock Higher?

• Announcement of top-line results from the completed Phase III clinical trial for Piclidenoson in psoriasis, which could lead to regulatory submission.
• Release of interim or final data from the ongoing Phase III clinical trial for Namodenoson in hepatocellular carcinoma (HCC), a critical step towards potential approval.
• Progress and data readouts from the Phase IIb clinical trial for Namodenoson in non-alcoholic steatohepatitis (NASH), potentially leading to advancement into Phase III.
• Further development and preclinical data for CF602 for erectile dysfunction, which could pave the way for IND submission and initiation of human trials.
• Expansion or new developments stemming from existing collaboration agreements with CMS Medical and Univo Pharmaceuticals, potentially accelerating drug development or commercialization efforts.

What Are the Key Risks for CANF?

• Financial-distress signal — its Altman Z-Score of -27.80 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Significant negative profitability and high R&D expenses (-1794.6% Profit Margin) necessitate continuous funding, posing a risk of future dilution for shareholders.
• Clinical trial failures or unexpected adverse events for any of its drug candidates (Piclidenoson, Namodenoson, CF602) could severely impact the company's valuation and future prospects.
• Delays in regulatory approvals or outright rejections by health authorities for its lead drug candidates, even after successful clinical trials, could hinder market entry.
• Heavy reliance on the success of its strategic partners, such as CMS Medical, for the commercialization and market penetration of its licensed drug candidates.
• Intense competition within the biotechnology sector from larger, better-funded pharmaceutical companies developing similar or alternative treatments for its target indications.

What Are the Growth Opportunities for CANF?

• **Piclidenoson in Psoriasis Market Penetration**: Piclidenoson has completed its Phase III clinical trial for psoriasis, a chronic autoimmune disease affecting millions globally. The global psoriasis treatment market is projected to reach over $30 billion by the late 2020s. Successful regulatory approval and subsequent commercialization, potentially through its existing collaboration with CMS Medical, could provide a significant revenue stream. The drug's unique mechanism of action targeting the A3 Adenosine Receptor (A3AR) could offer a differentiated profile in a competitive market, appealing to patients unresponsive to current therapies, with a potential market entry timeline in the next 2-4 years post-approval.
• **Namodenoson in Hepatocellular Carcinoma (HCC) Treatment**: Namodenoson is currently in a Phase III clinical trial for hepatocellular carcinoma, the most common type of liver cancer, which represents a severe unmet medical need with limited effective treatments. The global liver cancer therapeutics market is expected to grow significantly, potentially exceeding $5 billion by the early 2030s. Successful trial completion and regulatory approval could position Namodenoson as a vital new therapy, especially given its A3AR-targeting mechanism. This opportunity has a potential market entry timeline within the next 3-5 years, contingent on trial outcomes and regulatory processes.
• **Namodenoson in Non-alcoholic Steatohepatitis (NASH) Expansion**: With Namodenoson in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), Can-Fite is targeting a disease with a rapidly growing global prevalence and currently no approved pharmacological treatments. The NASH market is projected to be a multi-billion dollar opportunity, potentially reaching over $20 billion by the early 2030s. Advancing Namodenoson through later-stage clinical trials and towards regulatory submission could tap into this vast, underserved market, offering substantial long-term growth. The timeline for this opportunity extends further, likely 5-7+ years for full commercialization.
• **CF602 Development for Erectile Dysfunction**: The pre-clinical development of CF602 for erectile dysfunction (ED) represents an opportunity to enter a large and established market. The global ED drug market is valued in the billions of dollars annually, with a consistent demand for novel, effective, and safe treatment options. While in early stages, a successful development pathway could lead to a differentiated product, potentially offering advantages over existing therapies. This long-term growth opportunity could see clinical trials commencing within the next 2-3 years, with market potential several years beyond that.
• **Leveraging Strategic Collaborations and Biomarker Technology**: Can-Fite's license and collaboration agreement with CMS Medical for Piclidenoson and Namodenoson provides a commercialization pathway in specific territories, reducing the company's direct market entry burden. Furthermore, the collaboration with Univo Pharmaceuticals for cannabis components opens new avenues for therapeutic development. The development of a commercial predictive biomarker blood test kit for A3AR also represents a significant opportunity, potentially enabling a personalized medicine approach that could enhance drug efficacy and market adoption across its pipeline, thereby strengthening its competitive advantage and market positioning within the next 1-3 years.

What Opportunities Does CANF Have?

• Successful regulatory approval and commercialization of Piclidenoson for psoriasis, tapping into a multi-billion dollar market.
• Advancement and approval of Namodenoson for hepatocellular carcinoma and non-alcoholic steatohepatitis (NASH), addressing large unmet medical needs.
• Expansion of its pipeline through new drug candidates or indications, such as CF602 for erectile dysfunction.
• Leveraging its A3AR biomarker test to enhance drug efficacy, patient selection, and market adoption.
• Formation of additional strategic partnerships to expand geographic reach or accelerate development of pipeline assets.

What Threats Does CANF Face?

• High risk of clinical trial failures, which could lead to significant financial losses and delays.
• Intense competition from larger pharmaceutical companies with greater resources in targeted therapeutic areas.
• Stringent and evolving regulatory requirements that could delay or prevent drug approvals.
• Need for significant future capital raises, potentially leading to shareholder dilution, to fund ongoing R&D and commercialization efforts.
• Potential for adverse events or safety concerns arising during clinical trials or post-market, impacting drug viability.

What Are CANF's Competitive Advantages?

• Proprietary small molecule drug candidates (Piclidenoson, Namodenoson, CF602) with unique mechanisms of action targeting the A3 Adenosine Receptor (A3AR).
• Extensive intellectual property protection covering its A3AR platform technology and specific drug compounds.
• Development of a commercial predictive biomarker blood test kit for A3AR, potentially enabling personalized medicine and improving treatment outcomes.
• Strategic licensing and collaboration agreements with established pharmaceutical entities like CMS Medical, providing commercialization pathways and validation.
• Advanced clinical pipeline with lead candidates in Phase III trials, representing significant progress and de-risking compared to earlier-stage assets.

What Does CANF Do?

Can-Fite BioPharma Ltd., incorporated in 1994 as Can-Fite Technologies Ltd., later changed its name in January 2001, establishing its headquarters in Petah Tikva, Israel. The company operates as a clinical-stage biopharmaceutical entity, dedicated to the discovery and development of small molecule therapeutic products. Its core focus areas encompass the treatment of cancer, various liver inflammatory diseases, and erectile dysfunction, addressing significant medical needs with novel approaches. The company's pipeline is anchored by several key drug candidates. Piclidenoson, a lead candidate, has successfully completed its Phase III clinical trial for the treatment of psoriasis, a chronic autoimmune condition affecting the skin. Additionally, Piclidenoson has undergone a Phase II clinical trial for the treatment of COVID-19, exploring its potential in viral disease management. Another significant asset is Namodenoson, which is currently undergoing a Phase III clinical trial for the treatment of hepatocellular carcinoma (HCC), a primary liver cancer with limited therapeutic options. Namodenoson is also in a Phase IIb trial for non-alcoholic steatohepatitis (NASH), a progressive liver disease with a growing global prevalence and no approved treatments. Further diversifying its pipeline, Can-Fite BioPharma is developing CF602, which is in pre-clinical trial stages for the treatment of erectile dysfunction. Beyond drug candidates, the company is also developing a commercial predictive biomarker blood test kit for the Adenosine A3 Receptor (A3AR), which could potentially enable personalized medicine by identifying patients most likely to respond to its A3AR-targeting therapies. Strategic partnerships are integral to Can-Fite's model, including a license and collaboration agreement with CMS Medical for the development, manufacture, and commercialization of Piclidenoson and Namodenoson. Furthermore, a collaboration with Univo Pharmaceuticals aims to identify and co-develop specific formulations of cannabis components for various therapeutic applications, including cancer, inflammatory, autoimmune, and metabolic diseases, reflecting an innovative approach to drug discovery.

What Products and Services Does CANF Offer?

• Develops small molecule therapeutic products for various diseases.
• Conducts clinical trials for its drug candidates, including Phase III for psoriasis and hepatocellular carcinoma.
• Focuses on therapeutic areas such as cancer, liver inflammatory diseases, and erectile dysfunction.
• Advances lead drug candidates like Piclidenoson, Namodenoson, and CF602 through different clinical stages.
• Develops a commercial predictive biomarker blood test kit for the A3 Adenosine Receptor (A3AR).
• Engages in licensing and collaboration agreements for drug development, manufacturing, and commercialization.
• Collaborates on identifying and co-developing specific formulations of cannabis components for medical applications.

How Does CANF Make Money?

• Primarily generates value through the research and development of proprietary small molecule drug candidates.
• Aims to secure licensing agreements and milestone payments from pharmaceutical partners upon successful clinical development and regulatory achievements.
• Seeks to earn royalties from future sales of commercialized drugs by its partners in various territories.
• Develops a predictive biomarker test kit (A3AR) which could potentially generate diagnostic revenue or enhance the value proposition of its drug pipeline.
• Engages in co-development agreements to leverage external expertise and resources for drug discovery and formulation.

What Industry Does CANF Operate In?

Can-Fite BioPharma Ltd. operates within the highly specialized and capital-intensive biotechnology industry, a sub-sector of healthcare focused on developing novel biological and small molecule therapies. This industry is characterized by lengthy and costly drug development cycles, stringent regulatory approval processes, and a high rate of clinical trial failures. Can-Fite's positioning as a clinical-stage company developing small molecule therapeutics places it in a competitive landscape alongside numerous pharmaceutical and biotechnology firms pursuing treatments for cancer, inflammatory diseases, and metabolic disorders. The market for these therapeutic areas is substantial, driven by aging populations, increasing prevalence of chronic diseases, and ongoing demand for more effective and safer treatments. Success in this industry hinges on the ability to demonstrate significant efficacy and safety in clinical trials, secure regulatory approvals, and effectively commercialize products, often through strategic partnerships, to capture market share amidst intense competition and evolving scientific advancements.

Who Are CANF's Key Customers?

• Pharmaceutical and biotechnology companies seeking to license or acquire novel drug candidates with established clinical data.
• Healthcare providers and, ultimately, patients, upon successful commercialization of its therapeutic products.
• Strategic partners for co-development and research collaborations in new therapeutic areas or drug formulations.

FY2026 estForward Outlook

Wall Street analysts project Can-Fite BioPharma Ltd. revenue of about $20.6M for fiscal 2026, with EPS near $-0.68.

F-Score 1/9Financial Health

Can-Fite BioPharma Ltd.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -27.80 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -71.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.46 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.1%, the inverse of the P/E and a quick read on earnings relative to price.

Can-Fite BioPharma Ltd. (CANF) Valuation Context

Valued at $2.11M, CANF is classified as a micro-cap stock. Relative to its peer group, CANF's quantitative score of 49/100 is below the peer average of 76/100.

CANF Revenue & Earnings Trend

In Q2 2025, CANF generated $101K in top-line revenue, marking a sequential increase of 0.0%. The company recorded a net loss of $2.4M, with diluted EPS of $-0.21. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CANF averaged $-0.22 in diluted EPS.

Company Profile

Can-Fite BioPharma Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Petah Tikva, IL. The company is led by CEO Pnina Fishman. CANF has traded publicly since 2012.

CANF Financials

CANF Latest News

CANF Analyst Consensus

CANF MoonshotScore

Common Questions About CANF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources